Inflammatory breast cancer: A model for investigating cluster-based dissemination

npj Breast Cancer

Volumn 3, Issue 1, 2017, Pages

  Jolly, Mohit Kumar ^a   Boareto, Marcelo ^b   Debeb, Bisrat G ^c   Aceto, Nicola ^d   Farach Carson, Mary C ^a,e,f   Woodward, Wendy A ^c   Levine, Herbert ^a  

^a Rice University   (United States)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF BASEL   (Switzerland)

^e RICE UNIVERSITY   (United States)

^f UTHealth School of Dentistry   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; INTERLEUKIN 6; MICRORNA 141; NOTCH3 RECEPTOR; PROTEIN JAGGED 1; SMAD6 PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VIMENTIN;

APOPTOSIS; BRAIN METASTASIS; CELL COMMUNICATION; CELL INVASION; CIRCULATING TUMOR CELL; CYTOKINE RELEASE; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; INFLAMMATORY BREAST CANCER; LYMPH NODE METASTASIS; MESENCHYME CELL; PRIORITY JOURNAL; REVIEW;

EID: 85022088025     PISSN: None     EISSN: 23744677     Source Type: Journal    
DOI: 10.1038/s41523-017-0023-9     Document Type: Review

References (93)

1. Gupta, G. P. & Massagué, J. Cancer metastasis: building a framework. Cell 127, 679-695 (2006).
2. Luzzi, K. J. et al. Multistep nature of metastatic inefficiency. Am. J. Pathol. 153, 865-873 (1998).
3. Celià-Terrassa, T. & Kang, Y. Distinctive properties of metastasis- initiating cells. Genes Dev. 30, 892-908 (2016).
4. Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420-1428 (2009).
5. Thiery, J. P., Acloque, H., Huang, R. Y. J. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890 (2009).
6. Zheng, X. et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525-530 (2015).
7. Fischer, K. R. et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527, 472-476 (2015).
8. Somarelli, J. A. et al. Distinct routes to metastasis: plasticity-dependent and plasticity-independent pathways. Oncogene 35, 4302-4311 (2016).
9. Aceto, N. et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158, 1110-1122 (2014).
10. Cheung, K. J. et al. Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc. Natl Acad. Sci. USA 113, E854-E863 (2016).
11. Sarioglu, A. F. et al. A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat. Methods 12, 685-691 (2015).
12. Zeidman, I. & Buss, J. M. Transpulmonary passage of tumor cell emboli. Cancer Res. 12, 731-733 (1952).
13. Liotta, L. A., Klelnerman, J. & Saldel, G. M. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res. 36, 889-894 (1976).
14. Maddipati, R. & Stanger, B. Z. Pancreatic cancer metastases harbor evidence of polyclonality. Cancer Discov. 5, 1086-1097 (2015).
15. Morris, L. G. T. et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget 7, 10051-10063 (2016).
16. Au, S. H. et al. Clusters of circulating tumor cells traverse capillary-sized vessels. Proc. Natl. Acad. Sci. USA 113, 4947-4952 (2016).
17. Bronsert, P. et al. Cancer cell invasion and EMT marker expression: a threedimensional study of the human cancer-host interface. J. Pathol. 234, 410-422 (2014).
18. Grigore, A., Jolly, M. K., Jia, D., Farach-Carson, M. & Levine, H. Tumor budding: the name is EMT. Partial EMT. J. Clin. Med. 5, 51 (2016).
19. Boareto, M. et al. Notch-Jagged signaling can give rise to clusters of cells exhibiting a hybrid epithelial/mesenchymal phenotype. J. R. Soc. Interface 13, 20151106 (2016).
20. Friedl, P., Locker, J., Sahai, E. & Segall, J. E. Classifying collective cancer cell invasion. Nat. Cell. Biol. 14, 777-783 (2012).
21. Yang, J. et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927-939 (2004).
22. Li, W. & Kang, Y. Probing the fifty shades of EMT in metastasis. Trends Cancer 2, 65-66 (2016).
23. Cheung, K. J. & Ewald, A. J. Illuminating breast cancer invasion: diverse roles for cell-cell interactions. Curr. Opin. Cell. Biol. 30, 99-111 (2014).
24. Jolly, M. K. et al. Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. Front. Oncol. 5, 155 (2015).
25. Diepenbruck, M. & Christofori, G. Epithelial - mesenchymal transition (EMT) and metastasis: yes, no, maybe? Curr. Opin. Cell. Biol. 43, 7-13 (2016).
26. Nieto, M. A., Huang, R. Y., Jackson, R. A. & Thiery, J. P. EMT: 2016. Cell 166, 21-45 (2016).
27. Jeevan, D. S., Cooper, J. B., Braun, A., Murali, R. A. J. & Jhanwar-Uniyal, M. Molecular pathways mediating metastases to the brain via epithelial-to-mesenchymal transition: genes, proteins, and functional analysis. Anticancer Res. 36, 523-532 (2016).
28. Andriani, F. et al. Conversion to stem-cell state in response to microenvironmental cues is regulated by balance between epithelial and mesenchymal features in lung cancer cells. Mol. Oncol. 10, 253-271 (2016).
29. Jolly, M. K. et al. Stability of the hybrid epithelial/mesenchymal phentoype. Oncotarget 7, 27067-27084 (2016).
30. Zhang, Z. et al. Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget 5, 12383-12397 (2014).
31. Watanabe, K. et al. Mammary morphogenesis and regeneration require the inhibition of EMT at terminal end buds by Ovol2 transcriptional repressor. Dev. Cell. 29, 59-74 (2014).
32. Varma, S. et al. The transcription factors grainyhead-like 2 and NK2-homeobox 1 form a regulatory loop that coordinates lung epithelial cell morphogenesis and differentiation. J. Biol. Chem. 287, 37282-37295 (2012).
33. Li, D., Masiero, M., Banham, A. H. & Harris, A. L. The notch ligand JAGGED1 as a target for anti-tumor therapy. Front. Oncol. 4, 254 (2014).
34. Cheung, K. J. & Ewald, A. J. A collective route to metastasis: Seeding by tumor cell clusters. Science 352, 167-169 (2016).
35. Ribeiro, A. S. & Paredes, J. P-Cadherin linking breast cancer stem cells and invasion: a promising marker to identify an 'intermediate/metastable' EMT state. Front. Oncol. 4, 371 (2015).
36. Dang, T. T., Esparza, M. A., Maine, E. A., Westcott, J. M. & Pearson, G. W. δNp63α promotes breast cancer cell motility through the selective activation of components of the epithelial-to-mesenchymal transition program. Cancer Res. 75, 3925-3935 (2015).
37. Sarrió, D. et al. Functional characterization of E- and P-cadherin in invasive breast cancer cells. BMC Cancer. 9, 74 (2009).
38. Plutoni, C. et al. P-cadherin promotes collective cell migration via a Cdc42- mediated increase in mechanical forces. J. Cell. Biol. 212, 199-217 (2016).
39. Lodillinsky, C. et al. p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer. Oncogene 35, 344-357 (2016).
40. Mehrazarin, S. et al. p63 gene is regulated by grainyhead-Like 2 (GRHL2) through reciprocal feedback and determines epithelial phenotype in human keratinocytes. J. Biol. Chem. 290, 19999-20008 (2015).
41. Bae, Y. K., Choi, J. E., Kang, S. H. & Lee, S. J. Epithelial-mesenchymal transition phenotype is associated with clinicopathological factors that indicate aggressive biological behavior and poor clinical outcomes in invasive breast cancer. J. Breast Cancer 18, 256-263 (2015).
42. Yu, M. et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580-584 (2013).
43. Paredes, J. et al. Breast carcinomas that co-express E- and P-cadherin are associated with p120-catenin cytoplasmic localisation and poor patient survival. J. Clin. Pathol. 61, 856-862 (2008).
44. Somarelli, J. A., Boss, M.-K., Epstein, J. I., Armstrong, A. J. & Garcia-Blanco, M. A. Carcinosarcomas: tumors in transition? Histol. Histopathol. 30, 673-687 (2015).
45. Jolly, M. K. et al. Towards elucidating the connection between epithelial-mesenchymal transitions and stemness. J. R. Soc. Interface 11, 20140962 (2014).
46. Ombrato, L. & Malanchi, I. The EMT universe: space between cancer cell dissemination and metastasis initiation. Crit. Rev. Oncog. 19, 349-361 (2014).
47. Jolly, M. K. et al. Coupling the modules of EMT and stemness: a tunable 'stemness window' model. Oncotarget 6, 25161-25174 (2015).
48. Grosse-Wilde, A. et al. Stemness of the hybrid epithelial/mesenchymal state in breast cancer and its association with poor survival. PLoS ONE 10, e0126522 (2015).
49. Bierie, B. et al. Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells. Proc. Natl Acad. Sci. USA 114, E2337-E2346 (2017)
50. Lester, T. R. et al. Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res. Treat. 131, 41-48 (2012).
51. Nakaya, Y. & Sheng, G. EMT in developmental morphogenesis. Cancer Lett. 341, 9-15 (2013).
52. Camley, B. A., Zimmermann, J., Levine, H. & Rappel, W.-J. Emergent collective chemotaxis without single-cell gradient sensing. Phys. Rev. Lett. 116, 98101 (2016).
53. Camley, B. A., Zimmermann, J., Levine, H. & Rappel, W. J. Collective signal processing in cluster chemotaxis: roles of adaptation, amplification, and co-attraction in collective guidance. PLoS Comput. Biol. 12, 1-28 (2016).
54. Huang, R. Y.-J. et al. An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis. 4, e915 (2013).
55. Tripathi, S. C. et al. Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proc. Natl. Acad. Sci. USA 113, E1555-E1564 (2016).
56. Murray, N. P., Reyes, E., Tapia, P., Badínez, L. & Orellana, N. Differential expression of matrix metalloproteinase-2 expression in disseminated tumor cells and micrometastasis in bone marrow of patients with nonmetastatic and metastatic prostate cancer: theoretical considerations and clinical implications-an immunocy. Bone Marrow Res. 2012, 259351 (2012).
57. Grindel, B. J. et al. Matrilysin / matrix metalloproteinase-7 (MMP7) cleavage of perlecan/HSPG2 creates a molecular switch to alter prostate cancer cell behavior. Matrix Biol. 7, 64-76 (2014).
58. Ruscetti, M., Quach, B., Dadashian, E. L., Mulholland, D. J. & Hong, W. Tracking and functional characterization of epithelial-mesenchymal transition and mesenchymal tumor cells during prostate cancer metastasis. Cancer Res. 75, 2749-2759 (2015).
59. Strauss, R. et al. Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res. 69, 5115-5125 (2009).
60. Goldman, A. et al. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition. Nat. Commun. 6, 6139 (2015).
61. Debeb, B. G. et al. Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/β-catenin signaling. Stem Cells 30, 2366-2377 (2012).
62. Woodward, W. A. Inflammatory breast cancer: unique biological and therapeutic considerations. Lancet Oncol. 16, e568-e576 (2015).
63. Warren, L. E. et al. Inflammatory breast cancer and development of brain metastases: risk factors and outcomes. Breast Cancer Res. Treat. 151, 225-232 (2015).
64. Kleer, C. G., van Golen, K. L., Braun, T. & Merajver, S. D. Persistent E-cadherin expression in inflammatory breast cancer. Mod. Pathol. 14, 458-464 (2001).
65. Colpaert, C. G. et al. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br. J. Cancer 88, 718-725 (2003).
66. Rodriguez, F. J., Lewis-Tuffin, L. J. & Anastasiadis, P. Z. E-cadherin's dark side: possible role in tumor progression. Biochim. Biophys. Acta 1826, 23-31 (2012).
67. Cheung, K. J., Gabrielson, E., Werb, Z. & Ewald, A. J. Collective invasion in breast cancer requires a conserved basal epithelial program. Cell 155, 1639-1651 (2013).
68. Wang, H. et al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell 27, 193-210 (2015).
69. Mu, Z. et al. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Breast Cancer Res. Treat. 154, 563-571 (2015).
70. Wang, C. et al. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. Breast Cancer Res. Treat. (2016). doi:10.1007/ s10549-016-4026-2.
71. Ye, Y. et al. E-cadherin accumulation within the lymphovascular embolus of inflammatory breast cancer is due to altered trafficking. Anticancer Res. 30, 3903-3910 (2010).
72. Alpaugh, M. L., Tomlinson, J. S., Kasraeian, S. & Barsky, S. H. Cooperative role of Ecadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene 21, 3631-3643 (2002).
73. Bockhorn, M., Jain, R. K. & Munn, L. L. Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet Oncol. 8, 444-448 (2007).
74. Fang, J. H. et al. A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner. Hepatology 62, 452-465 (2015).
75. Tomlinson, J. S., Alpaugh, M. L. & Barsky, S. H. An intact overexpressed E-cadherin / α, β -catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res. 61, 5231-5241 (2001).
76. Cai, D. et al. Mechanical feedback through E-cadherin promotes direction sensing during collective cell migration. Cell 157, 1146-1159 (2014).
77. Shimamura, T. et al. A novel network profiling analysis reveals system changes in epithelial-mesenchymal transition. PLoS ONE 6, e20804 (2011).
78. Shen, X. & Kramer, R. H. Adhesion-mediated squamous cell carcinoma survival through ligand-independent activation of epidermal growth factor receptor. Am. J. Pathol. 165, 1315-1329 (2004).
79. Fernandez, S. V. et al. Inflammatory breast cancer (IBC): clues for targeted therapies. Breast Cancer Res. Treat. 140, 23-33 (2013).
80. Lu, M., Jolly, M. K., Levine, H., Onuchic, J. N. & Ben-Jacob, E. MicroRNA-based regulation of epithelial-hybrid-mesenchymal fate determination. Proc. Natl. Acad. Sci. USA 110, 18144-18149 (2013).
81. Leroy, P. & Mostov, K. E. Slug is required for cell survival during partial epithelialmesenchymal transition of HGF-induced tubulogenesis. J. Cell. Sci. 18, 1943-1952 (2007).
82. Robertson, F. M. et al. Genomic profiling of pre-clinical models of inflammatory breast cancer identifies a signature of epithelial plasticity and suppression of TGFβ. J. Clin. Exp. Pathol. 2, 119 (2012).
83. Guo, L. et al. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur. J. Cancer 46, 1692-1702 (2010).
84. Mohamed, M. M., Al-Raawi, D., Sabet, S. F. & El-Shinawi, M. Inflammatory breast cancer: New factors contribute to disease etiology: a review. J. Adv. Res. 5, 525-536 (2014).
85. Debeb, B. G. et al. Pre-clinical studies of notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res. 134, 495-510 (2015).
86. Wolfe, A. R. et al. Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models. Oncotarget. doi:10.18632/oncotarget.12694 (2016).
87. Woodward, W. A., Debeb, B. G., Xu, W. & Buchholz, T. A. Overcoming radiation resistance in inflammatory breast cancer. Cancer 116, 2840-2845 (2010).
88. Xiao, Y., Ye, Y., Yearsley, K., Jones, S. & Barsky, S. H. The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Oncogene 30, 287-300 (2011).
89. Gregory, P. A. et al. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol. Biol. Cell. 22, 1686-1698 (2011).
90. Chu, K., Boley, K. M., Moraes, R., Barsky, S. H. & Robertson, F. The paradox of Ecadherin: role in response to hypoxia in the tumor microenvironment and regulation of energy metabolism. Oncotarget 4, 446-462 (2013).
91. Lehman, H. L. et al. Modeling and characterization of inflammatory breast cancer emboli grown in vitro. Int. J. Cancer 132, 2283-2294 (2013).
92. Giamperi, S. et al. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat. Cell. Biol. 11, 1287-1296 (2009).
93. Debeb, B. G. et al. miR-141-mediated regulation of brain metastasis from breast cancer. J. Natl. Cancer. Inst. 108, djw026 (2016).